Integra LifeSciences Holdings
The 10-second takeaway
For the quarter ended March 31 (Q1), Integra LifeSciences Holdings met expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue was unchanged. Non-GAAP earnings per share contracted significantly. GAAP earnings per share shrank to a loss.
Margins contracted across the board.
Integra LifeSciences Holdings recorded revenue of $196.7 million. The 10 analysts polled by S&P Capital IQ expected revenue of $195.2 million on the same basis. GAAP reported sales were the same as the prior-year quarter's.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.39. The 10 earnings estimates compiled by S&P Capital IQ forecast $0.37 per share. Non-GAAP EPS of $0.39 for Q1 were 45% lower than the prior-year quarter's $0.71 per share. GAAP EPS were -$0.15 for Q1 against $0.23 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 59.2%, 510 basis points worse than the prior-year quarter. Operating margin was 0.0%, much worse than the prior-year quarter. Net margin was -2.1%, 550 basis points worse than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $208.3 million. On the bottom line, the average EPS estimate is $0.52.
Next year's average estimate for revenue is $845.9 million. The average EPS estimate is $2.46.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 153 members out of 163 rating the stock outperform, and 10 members rating it underperform. Among 52 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 49 give Integra LifeSciences Holdings a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Integra LifeSciences Holdings is outperform, with an average price target of $44.77.
Is Integra LifeSciences Holdings the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Integra LifeSciences Holdings to My Watchlist.